Jensen holds a PhD in Health Science from University of Copenhagen and a Master of Science in Biochemistry. After multiple years in the US as a graduate student and later holding a few Post Doc positions, Jensen joined the pharmaceutical industry as a leader of beta cell biology and pancreatic regeneration. Jensen then became the lead of large strategic initiatives as well as lead of experimental testing of an entire therapeutic portfolio. During this time, Jensen developed more and more interest in data science and computational biology, connecting data science with drug discovery. Jensen then became Deputy site head and strategic partner of a new research institute in Oxford, this time heading Computational Biology and Technologies. The focus was on data driven drug discovery as well as external partnerships with Academia and Biotech’s.
This led to a great opportunity to Join Boehringer-Ingelheim as Global Head of Computational Biologists Digital Sciences in October 2019 with initiatives and research groups across the major research sites Vienna (Austria), Ridgefield (United States) and Biberach (Germany). The ambition is here to shape the future drug portfolio by acting on novel biological insights generated from the application of state-of-the-art in silico methods to human disease data.